Eli Lilly (LLY) reported second quarter results which exceeded the consensus estimate. Shares of Eli Lilly were trading up about 5% in the pre-market trading on upbeat results and the encouraging outlook as well as the company’s decision to separate Elanco Animal Health business as a separate public company.
Non-GAAP earnings increased to $1.50 per share from last year’s $1.11 per share on revenue growth of 9% to $6.4 billion. However, the pharma giant posted a loss of $260 million or $0.25 per share compared to a profit of $1 billion or $0.95 per share in the prior year, hurt by acquisition-related charges.
The company cut down its 2018 reported earnings per share outlook to a range of $3.19-3.29 from the prior estimate of $4.52-4.62 due to the acquisition-related charges. Non-GAAP EPS outlook was lifted to a range of $5.40-5.50 from the prior estimate of $5.10-5.20, reflecting higher revenue and gross margin expectations.
Lilly lifted the fiscal year’s revenue target to a range of $24.0-24.5 billion versus the prior estimate of $23.7-24.2 billion, due to the strong pharmaceutical portfolio performance and higher collaboration revenue.
In a separate press release, Eli Lilly announced that it will separate the Elanco Animal Health division by filing an IPO for it. The company plans to take less than 20% of Elanco’s shares and the IPO process is expected to be completed in Q3 or Q4 2018.
“As it relates to U.S. drug pricing, the Administration has accelerated an important discussion, and Lilly is committed to working for greater affordability and access to our medicines,” said CEO David Ricks. Last week, President Trump thanked Novartis (NVS) and Pfizer (PFE) in a tweet for not hiking their drug prices.
The Indianapolis, Indiana-based drug company, which acquired ARMO Biosciences in May for $1.6 billion, inked a multi-year drug discovery deal with New Jersey-based Anima Biotech on Monday. Under the terms of the deal, Anima will receive $30 million in upfront payments and $14 million in research funding. If potential milestones are achieved, Anima could receive up to $1.05 billion. Lilly will be responsible for the clinical development and commercialization of products.
Shares of Eli Lilly, which achieved a new 52-week high ($90.13) on July 18, has crossed that and was trading at about $93 before the bell. The stock had increased about 5% both in the year-to-date and past 52 weeks period.
Cargo giant FedEx Corporation (NYSE: FDX) Thursday reported a decline in first-quarter adjusted earnings, despite an increase in revenues. The company also provided guidance for fiscal 2023. Net income, adjusted
Darden Restaurants, Inc. (NYSE:DRI) reported first quarter 2023 earnings results. Total sales increased 6.1% year-over-year to $2.4 billion, driven by blended same-restaurant sales growth of 4.2%. Net earnings amounted to
Accenture (NYSE: ACN) reported fourth quarter 2022 earnings results today. Total revenues were $15.4 billion, up 15% year-over-year in US dollars and up 22.4% in local currency. Net income attributable